Ractigen Therapy is a Nantong-based RNAa technology firm. It closed a Series B+ financing round of $30m.
SDIC Venture Capital led the round with participation from Eisai Co., Ltd., LC Ventures, CSSD Capital, Xianghe Capital.
The funds will be used by the company to fund several programs, from preclinical to clinical phases, and to scale up its oligonucleotide manufacturing capabilities.
Ractigen was founded in 2017 by Dr. Long-Cheng Li, a pioneer of the RNAa technology, and his longstanding colleagues Dr. Robert Place & Dr. Moorim Khang. The company is a preclinical pharmaceutical company that focuses on creating therapies based upon the RNAa platform. RNAa uses short duplex RNAs (small activating RNAs) to up-regulate specific endogenous genes, thereby boosting therapeutic protein manufacturing. To support its core platform, the company created the SCAD delivery method that allows for enhanced biodistribution through extrahepatic tissues and a rich pipeline to first-in-class candidates medicines for patients with unmet medical needs.